However, prostate adenocarcinoma with neuroendocrine differentiation not only show low PSA-values, but also no or low PSMA expression [30], which conflicts with a moderate SUVmax in most of these patients (Figure 2). Here, FOLH1 is linked to prostate adenocarcinoma.